Ann Dermatol.  2017 Feb;29(1):131-133. 10.5021/ad.2017.29.1.131.

Infliximab for Treatment of Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis Syndrome: A Case Report

• Hirohata A
• Hanafusa T
• Kawamoto T
• Ikegami R

• KMID: 2368051
• DOI: http://doi.org/10.5021/ad.2017.29.1.131

Abstract

No abstract available.

MeSH Terms

Acne Vulgaris*
Hyperostosis*
Infliximab*
Osteitis*
Synovitis*
Infliximab

Reference

1. Iqbal M, Kolodney MS. Acne fulminans with synovitis-acnepustulosis-hyperostosis-osteitis (SAPHO) syndrome treated with infliximab. J Am Acad Dermatol. 2005; 52:5 Suppl 1. S118–S120.

2. Yiu ZZ, Madan V, Griffiths CE. Acne conglobata and adalimumab: use of tumour necrosis factor-α antagonists in treatment-resistant acne conglobata, and review of the literature. Clin Exp Dermatol. 2015; 40:383–386.

3. Wagner AD, Andresen J, Jendro MC, Hülsemann JL, Zeidler H. Sustained response to tumor necrosis factor alpha-blocking agents in two patients with SAPHO syndrome. Arthritis Rheum. 2002; 46:1965–1968.

4. Olivieri I, Padula A, Ciancio G, Salvarani C, Niccoli L, Cantini F. Successful treatment of SAPHO syndrome with infliximab: report of two cases. Ann Rheum Dis. 2002; 61:375–376.

5. Delattre E, Guillot X, Godfrin-Valnet M, Prati C, Wendling D. SAPHO syndrome treatment with intravenous pamidronate. Retrospective study of 22 patients. Joint Bone Spine. 2014; 81:456–458.